Clinical Trial: A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum

U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07870538) titled 'A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum' on July 20.

Brief Summary: The goal of this clinical trial is to investigate how GLP-1 receptor analogs, such as semaglutide (Wegovy(R)), influence processes that determine eating behavior, binge eating, and weight regulation via the gut-brain axis. The main question it aims to answer is: to identify for whom semaglutide works best.

Participants will:

* undergo a semaglutide treatment for 6 months

* visit the clinic for 2-4 study checkup and tests

* wear a smartwatch and complete ...